When was Vyriad founded?

Vyriad was founded in 2016 and raised its 1st funding round 2 years after it was founded.

Where is Vyriad located?

Vyriad is headquartered in Rochester, United States.

How many employees does Vyriad have?

As of Jul 31, 2026, the latest employee count at Vyriad is 58.

Is Vyriad a funded company?

Vyriad is a funded company, having raised a total of $125M across 8 funding rounds to date. The company's 1st funding round was a $***** Conventional Debt round, raised on 2018.

When was the latest funding round of Vyriad?

Vyriad's latest funding was a $***** Series B round on Dec 23, 2025, with participation from 1 investor.

Where does Vyriad rank among its competitors?

Vyriad ranks 104th amongst 3282 active competitors, of which 1122 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Vyriad?

Vyriad's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Among them, Immuneel secured the most recent funding round in June, 2026.

Vyriad - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of oncolytic-virus-based immunotherapies for cancer treatment. The company focuses on the development of new oncolytic virus treatments that leverage Vyriad’s vesicular stomatitis virus (VSV) platform, as well as antibody discovery capabilities. The company's lead product is Voyager-V1 which addresses multiple cancer types.

Website: vyriad.com
Social
Email ID: *****@vyriad.com

Key Metrics

Founded Year

2016

Location

Rochester, United States

Stage

Series B

Total Funding

$125M in 8 rounds

Latest Funding Round

Series B, Dec 23, 2025, $*****

Investors

Harry Stine & 8 more

Ranked

104^th among 3282 active competitors

Employee Count

58 as on Jul 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3005 more

View Vyriad's full profile

Vyriad has raised a total funding of $125M over 8 rounds. Its first funding round was on 2018. Its latest funding round was a Series B round on Dec 23, 2025 for $*****. 1 investor participated in its latest round. Vyriad has 8 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Vyriad:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 23, 2025	4381923	Series B	7469098	2928373	6582444	3285719
May 17, 2022	5453181	Series B	5367505	1569713	8855188	Mayo Clinic & 3 more
Oct 30, 2019	9514816	Series A	6859804	4389061	1063911	2892290

Access funding benchmarks and valuations. Sign up today!

View details of Vyriad's funding rounds and investors

The founders of Vyriad is Stephen Russell.

Here are the details of Vyriad's key team members:

Stephen Russell: CEO & Founder of Vyriad.

View details of Vyriad's Founder profiles and Board Members

Vyriad's employee count trend

Vyriad has 58 employees as of Jul 26. Here is Vyriad's employee count trend over the years:

Uncover Vyriad's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Vyriad include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Here is the list of Top 10 competitors of Vyriad, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Google Ventures, Baillie Gifford & 17 others	75/100
3rd	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, Khosla Ventures & 23 others	71/100
104th	Vyriad 2016, Rochester (United States), Series B	Developer of oncolytic-virus-based immunotherapies for cancer treatment	$125M	Mirae Asset, Mayo Clinic & 7 others	63/100